公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
公司地址 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
電話號碼 +1 919 328-4400
傳真號碼 +1 919 328-4402
公司網頁 https://www.liquidia.com
員工數量 216
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Roger A. Jeffs, PhD Chief Executive Officer and Director 美元 824.00K 24/04/2026
Mr. Michael Kaseta Chief Financial Officer and Chief Operating Officer 美元 592.25K 24/04/2026
Mr. Jason Adair Chief Business Officer -- 24/04/2026
Mr. Russell Schundler General Counsel and Secretary 美元 540.75K 24/04/2026
Mr. Scott Moomaw Chief Commercial Officer 美元 449.90K 24/04/2026
Dr. Rajeev Saggar, M.D. Chief Medical Officer 美元 539.35K 24/04/2026
Ms. Dana Boyle Chief Accounting Officer -- 24/04/2026
Ms. Sarah Krepp Chief Human Resources Officer -- 24/04/2026
Dr. Sanjeev Khindri, M.B. Chief Development Officer -- 24/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Arthur S. Kirsch Independent Director 24/04/2026
Dr. Roger A. Jeffs, PhD Chief Executive Officer and Director 24/04/2026
Mr. David E. Johnson Independent Director 24/04/2026
Dr. Stephen Bloch,M.D. Chairman of the Board 24/04/2026
Mr. Paul B. Manning Independent Director 24/04/2026
Dr. Joanna Horobin, MB.Ch.B. Independent Director 24/04/2026
Mr. Ramandeep Singh Independent Director 24/04/2026
Ms. Katherine Rielly-Gauvin Independent Director 24/04/2026
Mr. Damian deGoa Independent Director 24/04/2026
 
所屬ETF (更新日期: 07/11/2026 03:28)
代號 名稱 佔比% ▼ 持有日期
AFMCFirst Trust Active Factor Mid Cap ETF0.01%29/10/2026
WSMLiShares MSCI World Small-Cap ETF0.005%30/10/2026
ITWOProShares Russell 2000 High Income ETF0.004%30/10/2026
HIAIAi Funds High Conv US Eq AI-Mgd ETF0.004%30/10/2026
EHLSEven Herd Long Short ETF0.004%30/10/2026
ACSGAmerican Century Small Cp Gr Insgts ETF0.004%30/10/2026
MKTNFederated Hermes MDT Market Neutral ETF0.004%31/10/2026
PILLDirexion Daily Phrmctcl&MdclBl3XShrsETF0.004%31/10/2026
URTYProShares UltraPro Russell20000.003%30/10/2026
MSMLiShares MSCI USA Small-Cap ETF0.003%30/10/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.003%31/10/2026
FTKIFirst Trust Small Cp BuyWrt Inc ETF0.003%29/10/2026
BKSEBNY Mellon US Small Cap Core Equity ETF0.002%31/10/2026
FLQSFranklin US Small Cap Mltfctr Idx ETF0.002%31/10/2026
UWMProShares Ultra Russell20000.002%30/10/2026
TILTNorthern Trust Mstar US Mkt Fac Tlt ETF0.002%30/10/2026
FSMLFranklin Small Cap Enhanced ETF0.002%31/10/2026
DCORDimensional US Core Equity 1 ETF0.002%24/09/2026
ESSCEventide Small Cap ETF0.002%30/10/2026
HELXFranklin Genomic Advancements ETF0.001%31/10/2026
  1    2    3   4    5    6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.